Royalty Pharma Plc (NASDAQ: RPRX) — Company Overview, News & Financial Data
Royalty Pharma acquires biopharmaceutical royalties to support innovation in healthcare.
Royalty Pharma Plc
Royalty Pharma Plc is a buyer of biopharmaceutical royalties and a provider of capital to the life sciences industry. The company funds biopharmaceutical innovation by acquiring royalties in commercialized approved biopharmaceuticals and late-stage development biopharmaceutical candidates, as well as by co-funding research and development programs and acquiring synthetic royalties. Its portfolio encompasses royalty interests in therapies across multiple disease areas, including rare diseases, oncology, neurology, immunology, metabolic disorders, and infectious diseases. Through strategic partnerships with academic institutions, non-profit organizations, biotechnology companies, and global pharmaceutical firms, the company structures transactions to assist partners in funding clinical trials, commercial launches, and strategic initiatives.
Snapshot
Operations
Products and/or services of Royalty Pharma Plc
- Existing Royalties: Acquisition of existing royalty rights from academic institutions, non-profit research organizations, individual inventors, and biotechnology companies derived from commercial sales of approved biopharmaceutical products and late-stage therapeutic candidates across diverse therapeutic categories globally.
- Synthetic Royalties: Provision of direct, non-dilutive capital to biopharmaceutical companies in exchange for newly created royalty streams based on future net sales of specific approved products or late-stage clinical candidates in development.
- Launch and Development Funding: Financial capital provided to pharmaceutical partners to support late-stage clinical development, clinical trial progression, regulatory filing processes, and global commercial launch activities in exchange for tailored royalty payments and milestone options.
- M&A Facilitation Funding: Strategic financing provided to biopharmaceutical corporate acquirers to help execute corporate acquisitions or asset purchases by monetizing prospective royalty streams or co-funding acquisition considerations in exchange for defined portfolio returns.
- Research and Development Co-Funding: Capital participation in targeted clinical development programs alongside pharmaceutical developers, covering specified research costs in exchange for tiered future royalty interests upon successful commercialization and regulatory approval.
- Portfolio Acquisitions: Direct purchasing of existing portfolios of pharmaceutical royalty interests from biopharmaceutical companies, healthcare investment funds, or financial institutions seeking liquidity, balance sheet optimization, or capital reallocation across global markets.
Royalty Pharma Plc executive team
- Pablo LegorretaFounder, Chairman of the Board & CEO
- Terrance P. CoyneExecutive VP & CFO
- Christopher HiteChairman of Partnering & Investments
- Marshall Jonathan UristHead of Research & Investments
- Greg ButzExecutive Vice President of Partnering & Investments
- Eric Cornelius SchneiderSenior VP & Chief Technology Officer
- James Folmar ReddochExecutive VP of Investments & Chief Scientific Officer
- George GrofikSenior VP and Head of Investor Relations & Communications
- Arthur Richard McGivernExecutive VP of Investment & Chief Legal Officer
- Molly SawayaExecutive VP & Head of Human Capital
Latest news about Royalty Pharma Plc
Dividend history
Dividends per share paid by Royalty Pharma Plc, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026(to date) | — | — | — | $0.9400 |
| FY2025 | — | — | — | $0.8800 |
| FY2024 | — | — | — | $0.8400 |
| FY2023 | — | — | — | $0.8000 |
| FY2022 | — | — | — | $0.7600 |
Key financials
Reported results for Royalty Pharma Plc, in USD.
- Market cap
- 38.4B
- Revenue (TTM)
- 2.5B
- P/E ratio
- 35.3
- EPS (diluted, TTM)
- 1.9
- Dividend yield
- 1.4%
- Profit margin
- 32.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 2.4B | 1.6B | 770.9M | |
| 2.3B | 1.3B | 859M | |
| 2.4B | 1.5B | 1.1B | |
| 2.2B | 307.1M | 42.8M |